About us - Enantia | Chemistry experts for pharma and biotech sectors

Who we are

Enantia is a Contract Research Organization (CRO) based in Barcelona, Spain, specialized in chemical and process development, and solid-state chemistry services for the pharmaceutical, biotech, material sciences and cosmetic industries. Founded in 2003, we have built a strong track record as a trusted partner in CMC development, from early-stage research through to clinical supply.

Our multidisciplinary team brings together chemists, crystallographers, and analytical scientists to deliver efficient, high-quality and flexible solutions to each customer’s needs. We thrive on tackling complex, high-stakes projects and have the technical and project management capabilities to deliver innovative results.

We work with biotech, mid-sized pharma companies, and large multinational corporations across the globe.

- Kilolab for process chemistry and chemical development solutions at Enantia Contract research organization (CRO).

- Crystal obtained in chemical development and solid-state chemistry services during at chemical Contract Research Organization (CRO).

Our expertise

We are experts in combining quality research in synthetic chemistry and solid-state development. Our services cover the full range of chemical development, including:

Route scouting and process optimization
Scale-up and kilo-scale custom synthesis
Impurity profiling and reference standards preparation
Solid form screening
Polymorph, salt, solvate, and cocrystal selection
Crystallization development
Chiral resolution and purification strategies

Having our origins in asymmetric synthesis, our knowledge extends today to non-chiral molecules, which also require rigorous development tailored to industrial needs—balancing scientific precision with time and cost efficiency.

We are especially recognized for our pioneering work in cocrystal technology, having contributed to one of the first FDA-approved API-API cocrystal, Seglentis®. Building on this expertise, we support the development of both crystalline and amorphous solid forms, including comprehensive crystallization development to ensure robust and scalable preparation methods.

Our laboratories are equipped with advanced analytical instrumentation, enabling us to work with even the most challenging compounds, including highly potent APIs (HPAPIs).

INVACO

PART OF INVEREADY

In December 2024, Enantia was acquired by Invaco, an Inveready company, a Spanish venture capital fund specialized in life sciences and health. The aim of this strategic movement is for Enantia to enter into a growth phase, aimed at further strengthening our capabilities and expanding our services.

The collaboration between Enantia and Inveready will facilitate expansion into new markets, as well as execute a targeted acquisition strategy to consolidate a group of specialized CROs serving the pharmaceutical, biotech, and materials industries.